Comparative toxicity of alloxan, N-alkylalloxans and ninhydrin to isolated pancreatic islets in vitro.

The in vitro toxicity of the diabetogenic agent alloxan as documented by the induction of beta cell necrosis was studied in isolated ob/ob mouse pancreatic islets. The effect of alloxan has been compared with that of a number of N-alkyl alloxan derivatives and with that of the structurally related compound, ninhydrin. Alloxan and its derivatives were selectively toxic to pancreatic beta cells, with other endocrine cells and exocrine parenchymal cells being well preserved, even at high concentration. In contrast, ninhydrin was selectively toxic to pancreatic beta cells only at comparatively low concentration, destroying all islet cell types at high concentrations. The ultrastructural changes induced by all the test compounds in pancreatic beta cells in vitro were very similar to those observed during the development of alloxan diabetes in vivo. The relative toxicity of the various compounds to pancreatic beta cells in vitro was not, however, related to their ability to cause diabetes in vivo. Indeed, the non-diabetogenic substances ninhydrin, N-butylalloxan and N-isobutylalloxan were very much more toxic to isolated islets than the diabetogenic compounds alloxan and N-methylalloxan. These results suggest that the differences in diabetogenicity among alloxan derivatives are not due to intrinsic differences in the susceptibility of the pancreatic beta cells to their toxicity, but may reflect differences in distribution or metabolism. High concentrations of glucose protected islets against the harmful effects of alloxan and its derivatives, but not those of ninhydrin. Low levels of glucose, and non-carbohydrate nutrients, afforded little protection, indicating that the effect of glucose is not due to the production of reducing equivalents within the cell, 3-O-Methylglucose, which protects against alloan diabetes in vivo, did not protect against alloxan toxicity in vitro. Since 3-O-methylglucose is known to prevent uptake of alloxan by pancreatic beta cells, it appears that uptake of alloxan by the cell is not a prerequisite for the induction of beta cell necrosis.

[1]  R. Munday,et al.  The relationship between the physicochemical properties and the biological effects of alloxan and several N-alkyl substituted alloxan derivatives. , 1993, The Journal of endocrinology.

[2]  M. Abdel‐Rahman,et al.  Protection of B cells against the effect of alloxan. , 1992, Toxicology letters.

[3]  R. Munday,et al.  Thiol-group reactivity, hydrophilicity and stability of alloxan, its reduction products and its N-methyl derivatives and a comparison with ninhydrin. , 1991, Biochemical pharmacology.

[4]  R. Munday,et al.  Glutathione-mediated redox cycling of alloxan. Mechanisms of superoxide dismutase inhibition and of metal-catalyzed OH. formation. , 1989, Biochemical pharmacology.

[5]  D. Eizirik,et al.  Functional restoration of cultured mouse pancreatic islets after in vitro exposure to alloxan. , 1988, Pharmacology & toxicology.

[6]  R. Munday Dialuric acid autoxidation. Effects of transition metals on the reaction rate and on the generation of "active oxygen" species. , 1988, Biochemical pharmacology.

[7]  L. Oberley Free radicals and diabetes. , 1988, Free radical biology & medicine.

[8]  H. Hansson,et al.  Relation between alloxan-induced plasma membrane dysfunction and inhibition of insulin secretion in pancreatic B-cells in vivo. , 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section A, Pathology.

[9]  R. Lorentzon,et al.  Uptake of labeled alloxan in mouse organs and mitochondria in vivo and in vitro. , 1983, Endocrinology.

[10]  W. Malaisse,et al.  Contrasting modes of action of D-glucose and 3-O-methyl-D-glucose as protectors of the rat pancreatic B-cell against alloxan. , 1983, Biochimica et biophysica acta.

[11]  D. Pipeleers,et al.  Selective uptake of alloxan by pancreatic B-cells. , 1982, The Biochemical journal.

[12]  W. Malaisse Alloxan toxicity to the pancreatic B-cell. A new hypothesis. , 1982, Biochemical pharmacology.

[13]  S. J. Cooperstein,et al.  15 – Action of Toxic Drugs on Islet Cells , 1981 .

[14]  C. D. Barry,et al.  Molecular requirements for recognition at glucoreceptor for insulin release. , 1979, Molecular pharmacology.

[15]  S. Lenzen Insulin secretion by isolated perfused rat and mouse pancreas. , 1979, The American journal of physiology.

[16]  R. Melmed Intermediate cells of the pancreas. An appraisal. , 1979, Gastroenterology.

[17]  R. Lorentzon,et al.  Stereological study of endoplasmic reticulum, golgi complex and secretory granules in the B-cells of normal and alloxan-treated mice , 1979, Virchows Archiv. B, Cell pathology including molecular pathology.

[18]  P. Lacy,et al.  Alloxan uptake by isolated rat islets of Langerhans. , 1978, Endocrinology.

[19]  S. J. Cooperstein,et al.  Effect of sulfhydryl-binding reagents on islet tissue permeability: protection and reversal by D-glucose and phlorizin. , 1978, The Journal of pharmacology and experimental therapeutics.

[20]  L. Boquist The endocrine pancreas in early alloxan diabetes. Including study of the alloxan inhibitory effect of feeding and some hexoses. , 2009, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.

[21]  D. Fleita,et al.  Reactions of Alloxan and Related Compounds , 1977 .

[22]  T. Tomita,et al.  The effect of alloxan on the permeability of isolated pancreatic islets to horseradish peroxidase , 1976, Virchows Archiv. B, Cell pathology.

[23]  L. Orci,et al.  Islet cell membrane alteration by diabetogenic drugs. , 1976, Laboratory investigation; a journal of technical methods and pathology.

[24]  M. Arcangeli,et al.  Studies of Alloxan Toxicity on the Beta Cell , 1975, Diabetes.

[25]  S. J. Holt,et al.  Intermediate cells of the pancreas. 3. Selective autophagy and destruction of beta-granules in intermediate cells of the rat pancreas induced by alloxan and streptozotocin. , 1973, Journal of cell science.

[26]  L. M. Beidler,et al.  Glucose and alloxan interactions in the pancreatic islets. , 1973, The American journal of physiology.

[27]  G. Dryhurst,et al.  Electrochemistry of Alloxan and Its N‐Methyl Derivatives in Aqueous Solution , 1971 .

[28]  B. Volk,et al.  Ultrastructural Pancreatic Beta-Cell Changes in Rabbits After Small and Large Doses of Alloxan , 1967, Diabetes.

[29]  A. Lazarow,et al.  EFFECT OF ALLOXAN ON PERMEABILITY OF PANCREATIC ISLET TISSUE IN VITRO. , 1964, The American journal of physiology.

[30]  W. Carter,et al.  Studies on Protection Against the Diabetogenic Effect of Alloxan by Glucose.∗ , 1962, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[31]  Cardeza Af,et al.  Electron microscopy of the pancreas in alloxan diabetes in the rat , 1958 .

[32]  E. Neuzil,et al.  Toxicité aiguë de la ninhydrine (hydrate d'indanetrione) pour la souris blanche. , 1957 .

[33]  G. Bruckmann,et al.  Preparation and properties of new derivatives of alloxan. , 1949, Journal of the American Chemical Society.

[34]  K. Bernhard,et al.  Beiträge zur Alloxan-Glucosurie , 1947 .

[35]  E. Wertheimer,et al.  Alloxan studies; the action of alloxan homologues and related compounds. , 1947, The Journal of biological chemistry.

[36]  P. Hidy Structural requirements for diabetogenic action in alloxan and related compounds. , 1946, The Journal of biological chemistry.

[37]  B. Waisbren,et al.  A Method for Consistent Induction of Chronic Hyperglycemia with Alloxan , 1945, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[38]  E. Wertheimer,et al.  Diabetogenic Action of Alloxan Derivatives , 1945, Nature.

[39]  H. Biltz,et al.  Über die Gewinnung von Dialursäuren und Uramilen , 1913 .

[40]  H. Biltz Alloxan-anhydrid und seine Methylderivate , 1912 .